Rutgers University Study of the Genetics of Blood Cancers
The Rutgers University Study of the Genetics of Blood Cancers
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This is an online research study to learn more about how genes affect your risk of blood cancers. No office visit is required and in return, participants may receive information about their genetic ancestry for free. This study will increase our understanding of the genetic basis of blood cancers, which is a crucial step in drug development to improve current treatment options. We seek a diverse population because diversity among participants maximizes the usefulness of the data. Participants will use our online study portal to answer questions about their health and provide their DNA via a saliva sample using a pre-paid mailer. Participation takes approximately 20 minutes. Participants will be invited to share data from their electronic health records, but this is not required for study participation. We keep participants engaged with short monthly newsletters.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tara Matise, PhD
- Phone Number: 848-445-3125
- Email: rugcc-blood-cancer@rutgers.edu
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
- Recruiting
- Rutgers University
-
Contact:
- Tara Matise, PhD
- Phone Number: 848-445-3125
- Email: rugcc@rutgers.edu
-
Principal Investigator:
- Tara Matise, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had blood cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.
Description
Inclusion Criteria:
- age 18 years or older
- currently living in the United States
- have access to the internet and a computer, laptop, tablet or smartphone
- willing to provide written informed consent for participation
- willing to provide DNA via a saliva sample using a collection kit mailed to your home
- willing to complete a survey with questions about health related to the study of blood cancer.
Exclusion Criteria:
- Not able to meet or fulfill any of the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: CROSS_SECTIONAL
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cases
Persons with blood cancer |
|
Controls
Persons who do not have blood cancer |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic risk variants associated with blood cancer
Time Frame: 2 years
|
Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype. |
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Tara Matise, PhD, Rutgers University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro2026000226
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Our study protocol does not include sharing IPD.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.